CN117794513A - 用于治疗上呼吸道微生物感染的肽酶制剂 - Google Patents

用于治疗上呼吸道微生物感染的肽酶制剂 Download PDF

Info

Publication number
CN117794513A
CN117794513A CN202280054111.3A CN202280054111A CN117794513A CN 117794513 A CN117794513 A CN 117794513A CN 202280054111 A CN202280054111 A CN 202280054111A CN 117794513 A CN117794513 A CN 117794513A
Authority
CN
China
Prior art keywords
composition
trypsin
virus
glycerol
xylitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280054111.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·克拉松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhimi Technology Co ltd
Original Assignee
Zhimi Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhimi Technology Co ltd filed Critical Zhimi Technology Co ltd
Publication of CN117794513A publication Critical patent/CN117794513A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280054111.3A 2021-08-03 2022-08-03 用于治疗上呼吸道微生物感染的肽酶制剂 Pending CN117794513A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21189429.0 2021-08-03
EP21189429 2021-08-03
PCT/EP2022/071842 WO2023012224A1 (en) 2021-08-03 2022-08-03 Peptidase formulation for treatment of microbial infections in the upper respiratory tract

Publications (1)

Publication Number Publication Date
CN117794513A true CN117794513A (zh) 2024-03-29

Family

ID=77207007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280054111.3A Pending CN117794513A (zh) 2021-08-03 2022-08-03 用于治疗上呼吸道微生物感染的肽酶制剂

Country Status (5)

Country Link
US (1) US20240173387A1 (cg-RX-API-DMAC10.html)
EP (1) EP4380549B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024528097A (cg-RX-API-DMAC10.html)
CN (1) CN117794513A (cg-RX-API-DMAC10.html)
WO (1) WO2023012224A1 (cg-RX-API-DMAC10.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599883B1 (en) * 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
CN100584376C (zh) * 2006-05-25 2010-01-27 广西亚热带作物研究所 治疗深度带痂糜烂性创伤的药物
EP3121272A1 (en) * 2015-07-24 2017-01-25 Zymetech ehf. Novel fish trypsin isoforms and their use
GB201800274D0 (en) * 2018-01-08 2018-02-21 Enzymatica Ab Novel treatments
US11013687B1 (en) * 2020-06-08 2021-05-25 Amcyte Pharma, Inc. Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2

Also Published As

Publication number Publication date
WO2023012224A1 (en) 2023-02-09
EP4380549A1 (en) 2024-06-12
EP4380549C0 (en) 2024-11-13
EP4380549B1 (en) 2024-11-13
US20240173387A1 (en) 2024-05-30
JP2024528097A (ja) 2024-07-26

Similar Documents

Publication Publication Date Title
ES3058227T3 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
RU2524304C2 (ru) Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций
US8709496B2 (en) Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract
US11826382B2 (en) Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US12042514B2 (en) Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
AU2021290329A1 (en) Method of prophylaxis of coronavirus and/or respiratory Syncytial virus infection
EP4380549B1 (en) Peptidase formulation for treatment of microbial infections in the upper respiratory tract
US20220040065A1 (en) Compositions and methods for prevention of viral infections and associated diseases
US20220133786A1 (en) THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES
WO2021191904A1 (en) Methods for preventing and treating viral infection
US20220025019A1 (en) Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
WO2023046680A1 (en) Combination of cetylpyridinium and benzydamine with virucidal effect on sars-cov-2
CN102369012B (zh) 氧化氘用于治疗病毒性呼吸道疾病的用途
US12485093B2 (en) Composition for use as an antiviral in the form of nasal drops and in nebulisers
TWI836258B (zh) 預防冠狀病毒及/或呼吸道融合病毒感染的方法
Pujarern et al. Lesson Learned from Antiseptic Mouthwash in COVID-19 Pandemic Then, Now and Future: A Systematic Review
US12414928B2 (en) Viral inactivation spray and gargling formulation
EP1596851A1 (en) The use of sodium 2-mercaptoethanesulfonate as antiviral agent
US20240000878A1 (en) Methods for treatment and/or prevention of viral infections
KR20250016360A (ko) 고농도 분자 요오드를 함유하는 급성 호흡기 감염성 질환 예방 및 치료 조성물 및 방법
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви
CN122005535A (zh) E3泛素连接酶抑制剂在制备变应性鼻炎药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination